Premium
Effective Bioactive Treatment for Ewing Sarcoma
Author(s) -
Randolph Priscilla,
Ibrahim Salam A.,
HolmesMcNary Minnie
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.720.10
Subject(s) - sarcoma , medicine , soft tissue sarcoma , oncology , osteosarcoma , cancer research , ewing's sarcoma , cancer , chemotherapy , resveratrol , pathology , pharmacology
Ewing sarcoma (EWS) is a rare form of bone cancer that is found primarily in Caucasian children and young adults. Ewing sarcoma is characterized as a highly malignant tumor that is found in both bone and soft tissues. However, when EWS is detected early the overall survival rate is 60%. Current treatment has been limited to chemotherapy, radiation and surgery or a combination of these treatment modalities. Previous research by our lab and others demonstrate the beneficial cancer prevention properties of trans‐Resveratrol (RES) a bioactive nutrient. These former studies are the impetus for our present studies. Therefore, we hypothesize that RES will be an effective combinatorial treatment for EWS. Our studies with human‐derived EWS cells show significant apoptotic cell death and differential gene expression during exposure with either TNF‐alpha, RES, irradiation (IRR) alone or in combination. Our studies clearly demonstrate an effective alternative treatment modality for EWS. Supported in part by NSF‐AGEP (PR), United States Department of Agriculture (USDA‐SI, PR), Faculty Initiated Grant (MHM), College of Arts and Sciences. Grant Funding Source : NCAT, USDA